Matrix metalloproteinase activity in early-stage lung cancer

Onkologie(Czech Republic)

Volumn 36, Issue 5, 2013, Pages 256-259

  Weng, Yuan ^a   Cai, Ming ^a   Zhu, Jun ^a   Geng, Jiqun ^a   Zhu, Koujun ^a   Jin, Xiaoyin ^a   Ding, Weijun ^a  

^a Soochow University   (China)

Author keywords

Casein zymography; Gelatin zymography; Lung cancer; Matrix metalloproteinase

Indexed keywords

CASEIN; GELATIN; GELATINASE A; GELATINASE B; MATRILYSIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; ZYMOGRAPHY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878242768     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000350304     Document Type: Article

References (11)

1. Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000;36: 1621-1630.
2. Roy R, Yang J, Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27: 5287-5297.
3. Leinonen T, Pirinen R, Böhm J, Johansson R, Ropponen K, Kosma VM: Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicpathological factors, betacatenin and prognosis. Lung Cancer 2006;51: 313- 321.
4. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB: A phase I dose escalation study of the matrix metalloproteinase inhibitor BAYl2-9566 administered orally in patients with advanced solid tumor. Ann Oncol 2000;11: 1579-1584.
5. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I: Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 2002; 8: 1152-1156.
6. Davies B, Waxman J, Wasan H, Abel P. Williams G. Krause T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteinase in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53: 5365-5369.
7. Schütz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C: Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 2002;23: 179-184.
8. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000;190: 150-156.
9. Atkinson JM, Pennington CJ, Martin SW, Anikin VA, Mearns AJ, Loadman PM, Edwards DR, Gill JH: Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 2007;43: 1764-1771.
10. Suzuki M, Lizasa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H, Suzuki H: Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small cell lung cancer. Invasion Metastasis 1999;18: 134-141.
11. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumors. Int J Cancer 1991;48: 550-556.